{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:31:28Z","timestamp":1787754688603,"version":"build-2784847793"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["204841\/Z\/16\/Z"],"award-info":[{"award-number":["204841\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Comorbidities present considerable challenges to cancer treatment and care. However, little is known about the effect of comorbidity on cancer treatment decisions across a wide range of cancer types and treatment modalities. Harnessing a cohort of 280,543 patients spanning 19 site-specific cancers, we explored pan-cancer frequencies of 109 comorbidities. Multinomial logistic regression was used to analyse the relationship between comorbidities and cancer treatment types, while binomial logistic regression examined the association between comorbidities and chemotherapy drug types, adjusting for demographic and clinical factors. Patients with comorbidity exhibited lower odds of receiving chemotherapy and multimodality treatment. End-stage renal disease was significantly associated with a decreased odds of receiving chemotherapy and surgery. Patients with prostate cancer who have comorbid non-acute cystitis, obstructive and reflux uropathy, urolithiasis, or hypertension were less likely to receive chemotherapy. Among patients with breast cancer, dementia, left bundle branch block, peripheral arterial disease, epilepsy, Barrett\u2019s oesophagus, ischaemic stroke, unstable angina and asthma were associated with lower odds of receiving multimodal chemotherapy, radiotherapy and surgery. Comorbidity is also consistently associated with the lower odds of receiving chemotherapy when comparing across 10 drug classes. Patients with comorbid dementia, intracerebral haemorrhage, subarachnoid haemorrhage, oesophageal varices, liver fibrosis sclerosis and cirrhosis and secondary pulmonary hypertension were less likely to receive antimetabolites. Comorbidity can influence the effectiveness and tolerability of cancer treatment and ultimately, prognosis. Multi-specialty collaborative care is essential for the management of comorbidity during cancer treatment, including prophylactic measures to manage toxicities.<\/jats:p>","DOI":"10.1038\/s41598-024-51161-0","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T15:03:26Z","timestamp":1704294206000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pan-cancer analyses of the associations between 109 pre-existing conditions and cancer treatment patterns across 19 adult cancers"],"prefix":"10.1038","volume":"14","author":[{"given":"Wai Hoong","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvina G.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"key":"51161_CR1","unstructured":"National Institute for Health and Care Excellence. Lung Cancer: Diagnosis and Management."},{"key":"51161_CR2","unstructured":"National Institute for Health and Care Excellence. Early and Locally Advanced Breast Cancer: Diagnosis and Management."},{"key":"51161_CR3","unstructured":"National Institute for Health and Care Excellence. Prostate Cancer: Diagnosis and Management."},{"key":"51161_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1634\/theoncologist.2017-0687","volume":"24","author":"N Duma","year":"2019","unstructured":"Duma, N. et al. Characterization of comorbidities limiting the recruitment of patients in early phase clinical trials. Oncologist 24, 96\u2013102 (2019).","journal-title":"Oncologist"},{"key":"51161_CR5","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1001\/jamaoncol.2018.5953","volume":"5","author":"JM Unger","year":"2019","unstructured":"Unger, J. M., Hershman, D. L., Fleury, M. E. & Vaidya, R. Association of patient comorbid conditions with cancer clinical trial participation. JAMA Oncol. 5, 326\u2013333 (2019).","journal-title":"JAMA Oncol."},{"key":"51161_CR6","unstructured":"About the National Cancer Registration and Analysis Service. NCRAS. http:\/\/www.ncin.org.uk\/about_ncin\/."},{"key":"51161_CR7","unstructured":"GOV.UK. English Indices of Deprivation."},{"key":"51161_CR8","unstructured":"HDR UK. Phenotype Library. https:\/\/phenotypes.healthdatagateway.org\/."},{"key":"51161_CR9","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1016\/S2589-7500(19)30012-3","volume":"1","author":"V Kuan","year":"2019","unstructured":"Kuan, V. et al. A chronological map of 308 physical and mental health conditions from 4 million individuals in the English National Health Service. Lancet Dig. Health 1, e63-77 (2019).","journal-title":"Lancet Dig. Health"},{"key":"51161_CR10","volume-title":"Resampling Methods: A Practical Guide to Data Analysis","author":"PI Good","year":"2006","unstructured":"Good, P. I. Estimating population parameters. In Resampling Methods: A Practical Guide to Data Analysis (ed. Good, P. I.) (Springer, 2006)."},{"key":"51161_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/JCO.2010.31.3049","volume":"29","author":"L Lee","year":"2011","unstructured":"Lee, L., Cheung, W. Y., Atkinson, E. & Krzyzanowska, M. K. Impact of comorbidity on chemotherapy use and outcomes in solid tumors: A systematic review. J. Clin. Oncol. 29, 106\u2013117 (2011).","journal-title":"J. Clin. Oncol."},{"key":"51161_CR12","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/sj.bjc.6604298","volume":"98","author":"J Wright","year":"2008","unstructured":"Wright, J., Doan, T., McBride, R., Jacobson, J. & Hershman, D. Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival. Br. J. Cancer 98, 1197\u20131203 (2008).","journal-title":"Br. J. Cancer"},{"key":"51161_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-020-07487-9","volume":"20","author":"A Batra","year":"2020","unstructured":"Batra, A., Sheka, D., Kong, S. & Cheung, W. Y. Impact of pre-existing cardiovascular disease on treatment patterns and survival outcomes in patients with lung cancer. BMC Cancer 20, 1\u201316 (2020).","journal-title":"BMC Cancer"},{"key":"51161_CR14","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1093\/annonc\/mdp482","volume":"21","author":"L Van Steenbergen","year":"2010","unstructured":"Van Steenbergen, L. et al. Large age and hospital-dependent variation in administration of adjuvant chemotherapy for stage III colon cancer in southern Netherlands. Ann. Oncol. 21, 1273\u20131278 (2010).","journal-title":"Ann. Oncol."},{"key":"51161_CR15","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1093\/gerona\/glp180","volume":"65","author":"SM Koroukian","year":"2010","unstructured":"Koroukian, S. M. et al. Comorbidities, functional limitations, and geriatric syndromes in relation to treatment and survival patterns among elders with colorectal cancer. J. Gerontol. Ser. A Biomed. Sci. Med. Sci. 65, 322\u2013329 (2010).","journal-title":"J. Gerontol. Ser. A Biomed. Sci. Med. Sci."},{"key":"51161_CR16","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1093\/annonc\/mds576","volume":"24","author":"K Hoeben","year":"2013","unstructured":"Hoeben, K. et al. Treatment and complications in elderly stage III colon cancer patients in the Netherlands. Ann. Oncol. 24, 974\u2013979 (2013).","journal-title":"Ann. Oncol."},{"key":"51161_CR17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10549-012-2176-4","volume":"135","author":"A Berglund","year":"2012","unstructured":"Berglund, A. et al. Impact of comorbidity on management and mortality in women diagnosed with breast cancer. Breast Cancer Res. Treat. 135, 281\u2013289 (2012).","journal-title":"Breast Cancer Res. Treat."},{"key":"51161_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-9-116","volume":"9","author":"D Sarfati","year":"2009","unstructured":"Sarfati, D. et al. The effect of comorbidity on the use of adjuvant chemotherapy and survival from colon cancer: A retrospective cohort study. BMC Cancer 9, 1\u201310 (2009).","journal-title":"BMC Cancer"},{"key":"51161_CR19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ygyno.2012.07.001","volume":"127","author":"TL J\u00f8rgensen","year":"2012","unstructured":"J\u00f8rgensen, T. L. et al. Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients. Gynecol. Oncol. 127, 367\u2013374 (2012).","journal-title":"Gynecol. Oncol."},{"key":"51161_CR20","doi-asserted-by":"publisher","first-page":"s275","DOI":"10.1111\/j.1532-5415.2009.02511.x","volume":"57","author":"SM Koroukian","year":"2009","unstructured":"Koroukian, S. M. Assessment and interpretation of comorbidity burden in older adults with cancer. J. Am. Geriatr. Soc. 57, s275\u2013s278 (2009).","journal-title":"J. Am. Geriatr. Soc."},{"key":"51161_CR21","first-page":"213","volume":"7","author":"V Sundararajan","year":"2001","unstructured":"Sundararajan, V., Grann, V. R., Jacobson, J. S., Ahsan, H. & Neugut, A. I. Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: A population-based study. Cancer J. 7, 213\u2013218 (2001).","journal-title":"Cancer J."},{"key":"51161_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00405-004-0744-x","volume":"262","author":"W Derks","year":"2005","unstructured":"Derks, W., De Leeuw, J., Hordijk, G. & Winnubst, J. Reasons for non-standard treatment in elderly patients with advanced head and neck cancer. Eur. Arch. Oto-Rhino-Laryngol. Head Neck 262, 21\u201326 (2005).","journal-title":"Eur. Arch. Oto-Rhino-Laryngol. Head Neck"},{"key":"51161_CR23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.lungcan.2004.03.011","volume":"46","author":"J De Rijke","year":"2004","unstructured":"De Rijke, J. et al. Influence of age, comorbidity and performance status on the choice of treatment for patients with non-small cell lung cancer; results of a population-based study. Lung Cancer 46, 233\u2013245 (2004).","journal-title":"Lung Cancer"},{"key":"51161_CR24","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1002\/cncr.26646","volume":"118","author":"M Extermann","year":"2012","unstructured":"Extermann, M. et al. Predicting the risk of chemotherapy toxicity in older patients: The chemotherapy risk assessment scale for high-age patients (CRASH) score. Cancer 118, 3377\u20133386 (2012).","journal-title":"Cancer"},{"key":"51161_CR25","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","volume":"53","author":"CN Klabunde","year":"2000","unstructured":"Klabunde, C. N., Potosky, A. L., Legler, J. M. & Warren, J. L. Development of a comorbidity index using physician claims data. J. Clin. Epidemiol. 53, 1258\u20131267 (2000).","journal-title":"J. Clin. Epidemiol."},{"key":"51161_CR26","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1001\/jama.291.20.2441","volume":"291","author":"JF Piccirillo","year":"2004","unstructured":"Piccirillo, J. F., Tierney, R. M., Costas, I., Grove, L. & Spitznagel, E. L. Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291, 2441\u20132447 (2004).","journal-title":"JAMA"},{"key":"51161_CR27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3747\/co.24.3355","volume":"24","author":"S Tabchi","year":"2017","unstructured":"Tabchi, S., Kassouf, E., Florescu, M., Tehfe, M. & Blais, N. Factors influencing treatment selection and survival in advanced lung cancer. Curr. Oncol. 24, 115\u2013122 (2017).","journal-title":"Curr. Oncol."},{"key":"51161_CR28","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.6004\/jnccn.2020.7578","volume":"18","author":"J Abi Jaoude","year":"2020","unstructured":"Abi Jaoude, J. et al. Performance status restriction in phase III cancer clinical trials. J. Natl. Compr. Cancer Netw. 18, 1322\u20131326 (2020).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"51161_CR29","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1056\/NEJMoa1000678","volume":"363","author":"JS Temel","year":"2010","unstructured":"Temel, J. S. et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N. Engl. J. Med. 363, 733\u2013742 (2010).","journal-title":"N. Engl. J. Med."},{"key":"51161_CR30","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1054\/bjoc.2001.2162","volume":"85","author":"M Ando","year":"2001","unstructured":"Ando, M. et al. Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br. J. Cancer 85, 1634\u20131639 (2001).","journal-title":"Br. J. Cancer"},{"key":"51161_CR31","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1097\/JTO.0b013e318186a272","volume":"3","author":"E Dajczman","year":"2008","unstructured":"Dajczman, E. et al. Should patient-rated performance status affect treatment decisions in advanced lung cancer? J. Thorac. Oncol. 3, 1133\u20131136 (2008).","journal-title":"J. Thorac. Oncol."},{"key":"51161_CR32","first-page":"4151","volume":"10","author":"V Chiruvella","year":"2020","unstructured":"Chiruvella, V., Annamaraju, P. & Guddati, A. K. Management of nephrotoxicity of chemotherapy and targeted agents: 2020. Am. J. Cancer Res. 10, 4151 (2020).","journal-title":"Am. J. Cancer Res."},{"key":"51161_CR33","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s11096-013-9912-7","volume":"36","author":"Y Bennis","year":"2014","unstructured":"Bennis, Y. et al. Cisplatin dose adjustment in patients with renal impairment, which recommendations should we follow? Int. J. Clin. Pharm. 36, 420\u2013429 (2014).","journal-title":"Int. J. Clin. Pharm."},{"key":"51161_CR34","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1093\/jat\/28.2.138","volume":"28","author":"C Charlier","year":"2004","unstructured":"Charlier, C., Kintz, P., Dubois, N. & Plomteux, G. Fatal overdosage with cisplatin. J. Anal. Toxicol. 28, 138\u2013140 (2004).","journal-title":"J. Anal. Toxicol."},{"key":"51161_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2466-14-14","volume":"14","author":"N Hashimoto","year":"2014","unstructured":"Hashimoto, N. et al. Clinical impact of prevalence and severity of COPD on the decision-making process for therapeutic management of lung cancer patients. BMC Pulm. Med. 14, 1\u20139 (2014).","journal-title":"BMC Pulm. Med."},{"key":"51161_CR36","first-page":"124","volume":"61","author":"Y Sekine","year":"2013","unstructured":"Sekine, Y., Suzuki, H., Yamada, Y., Koh, E. & Yoshino, I. Severity of chronic obstructive pulmonary disease and its relationship to lung cancer prognosis after surgical resection. Thorac. Cardiovasc. Surg. 61, 124\u2013130 (2013).","journal-title":"Thorac. Cardiovasc. Surg."},{"key":"51161_CR37","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.2147\/COPD.S105206","volume":"11","author":"ES Kim","year":"2016","unstructured":"Kim, E. S. et al. Prevalence of and risk factors for postoperative pulmonary complications after lung cancer surgery in patients with early-stage COPD. Int. J. Chron. Obstruct. Pulm. Dis. 11, 1317 (2016).","journal-title":"Int. J. Chron. Obstruct. Pulm. Dis."},{"key":"51161_CR38","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S1470-2045(05)01736-5","volume":"6","author":"I Wolf","year":"2005","unstructured":"Wolf, I., Sadetzki, S., Catane, R., Karasik, A. & Kaufman, B. Diabetes mellitus and breast cancer. Lancet Oncol. 6, 103\u2013111 (2005).","journal-title":"Lancet Oncol."},{"key":"51161_CR39","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1075-122X.2004.21323.x","volume":"10","author":"J Engel","year":"2004","unstructured":"Engel, J., Kerr, J., Schlesinger-Raab, A., Sauer, H. & H\u00f6lzel, D. Quality of life following breast-conserving therapy or mastectomy: Results of a 5-year prospective study. Breast J. 10, 223\u2013231 (2004).","journal-title":"Breast J."},{"key":"51161_CR40","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1634\/theoncologist.7-2-136","volume":"7","author":"BH Chon","year":"2002","unstructured":"Chon, B. H. & Loeffler, J. S. The effect of nonmalignant systemic disease on tolerance to radiation therapy. The Oncologist 7, 136\u2013143 (2002).","journal-title":"The Oncologist"},{"key":"51161_CR41","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1006\/gyno.1996.0090","volume":"61","author":"H Gogas","year":"1996","unstructured":"Gogas, H. et al. The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. Gynecol. Oncol. 61, 22\u201326 (1996).","journal-title":"Gynecol. Oncol."},{"key":"51161_CR42","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa1209825","volume":"368","author":"SC Darby","year":"2013","unstructured":"Darby, S. C. et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N. Engl. J. Med. 368, 987\u2013998 (2013).","journal-title":"N. Engl. J. Med."},{"key":"51161_CR43","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1200\/JCO.2016.72.0722","volume":"35","author":"C Taylor","year":"2017","unstructured":"Taylor, C. et al. Estimating the risks of breast cancer radiotherapy: Evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J. Clin. Oncol. 35, 1641 (2017).","journal-title":"J. Clin. Oncol."},{"key":"51161_CR44","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1001\/jama.290.21.2831","volume":"290","author":"MC Hull","year":"2003","unstructured":"Hull, M. C., Morris, C. G., Pepine, C. J. & Mendenhall, N. P. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 290, 2831\u20132837 (2003).","journal-title":"JAMA"},{"key":"51161_CR45","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S0735-1097(03)00759-9","volume":"42","author":"PA Heidenreich","year":"2003","unstructured":"Heidenreich, P. A., Hancock, S. L., Lee, B. K., Mariscal, C. S. & Schnittger, I. Asymptomatic cardiac disease following mediastinal irradiation. J. Am. Coll. Cardiol. 42, 743\u2013749 (2003).","journal-title":"J. Am. Coll. Cardiol."},{"key":"51161_CR46","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/ehjci\/jet123","volume":"14","author":"P Lancellotti","year":"2013","unstructured":"Lancellotti, P. et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: A report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur. Heart J. Cardiovasc. Imaging 14, 721\u2013740 (2013).","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"51161_CR47","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cardfail.2013.07.007","volume":"19","author":"M Ammon","year":"2013","unstructured":"Ammon, M. et al. Cardiovascular management of cancer patients with chemotherapy-associated left ventricular systolic dysfunction in real-world clinical practice. J. Card. Fail. 19, 629\u2013634 (2013).","journal-title":"J. Card. Fail."},{"key":"51161_CR48","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","volume":"31","author":"G Curigliano","year":"2020","unstructured":"Curigliano, G. et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann. Oncol. 31, 171\u2013190 (2020).","journal-title":"Ann. Oncol."},{"key":"51161_CR49","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1161\/CIRCULATIONAHA.116.023463","volume":"135","author":"HK Narayan","year":"2017","unstructured":"Narayan, H. K. et al. Detailed echocardiographic phenotyping in breast cancer patients: Associations with ejection fraction decline, recovery, and heart failure symptoms over 3 years of follow-up. Circulation 135, 1397\u20131412 (2017).","journal-title":"Circulation"},{"key":"51161_CR50","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","volume":"114","author":"D Cardinale","year":"2006","unstructured":"Cardinale, D. et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114, 2474\u20132481 (2006).","journal-title":"Circulation"},{"key":"51161_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100248","author":"WH Chang","year":"2021","unstructured":"Chang, W. H. et al. Late effects of cancer in children, teenagers and young adults: population-based study on the burden of 183 conditions, in-patient and critical care admissions and years of life lost. Lancet Reg. Health Eur. https:\/\/doi.org\/10.1016\/j.lanepe.2021.100248 (2021).","journal-title":"Lancet Reg. Health Eur."},{"key":"51161_CR52","doi-asserted-by":"publisher","first-page":"100433","DOI":"10.1016\/j.lanepe.2022.100433","volume":"20","author":"S-C Chung","year":"2022","unstructured":"Chung, S.-C. et al. Multimorbidity patterns and risk of hospitalisation in children: A population cohort study of 3.6 million children in England, with illustrative examples from childhood cancer survivors. Lancet Reg. Health Eur. 20, 100433 (2022).","journal-title":"Lancet Reg. Health Eur."},{"key":"51161_CR53","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/thx.2008.096560","volume":"64","author":"SM Smith","year":"2009","unstructured":"Smith, S. M. et al. Factors contributing to the time taken to consult with symptoms of lung cancer: A cross-sectional study. Thorax 64, 523\u2013531 (2009).","journal-title":"Thorax"},{"key":"51161_CR54","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1479-8301.2010.00344.x","volume":"11","author":"S Iritani","year":"2011","unstructured":"Iritani, S., Tohgi, M., Miyata, H. & Ohi, G. Impact of dementia on cancer discovery and pain. Psychogeriatrics 11, 6\u201313 (2011).","journal-title":"Psychogeriatrics"},{"key":"51161_CR55","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/cncr.25655","volume":"117","author":"CR Friese","year":"2011","unstructured":"Friese, C. R. et al. Timeliness and quality of diagnostic care for medicare recipients with chronic lymphocytic leukemia. Cancer 117, 1470\u20131477 (2011).","journal-title":"Cancer"},{"key":"51161_CR56","doi-asserted-by":"publisher","first-page":"e018403","DOI":"10.1161\/JAHA.120.018403","volume":"9","author":"J Alexandre","year":"2020","unstructured":"Alexandre, J. et al. Cardiovascular toxicity related to cancer treatment: A pragmatic approach to the American and European cardio-oncology guidelines. J. Am. Heart Assoc. 9, e018403 (2020).","journal-title":"J. Am. Heart Assoc."},{"key":"51161_CR57","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1093\/ckj\/sfaa127","volume":"14","author":"L Cosmai","year":"2021","unstructured":"Cosmai, L. et al. Preventive strategies for acute kidney injury in cancer patients. Clin. Kidney J. 14, 70\u201383 (2021).","journal-title":"Clin. Kidney J."},{"key":"51161_CR58","doi-asserted-by":"publisher","first-page":"e036495","DOI":"10.1136\/bmjopen-2019-036495","volume":"10","author":"J Bossert","year":"2020","unstructured":"Bossert, J. et al. What patients with lung cancer with comorbidity tell us about interprofessional collaborative care across healthcare sectors: Qualitative interview study. BMJ Open 10, e036495 (2020).","journal-title":"BMJ Open"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51161-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51161-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51161-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T15:07:14Z","timestamp":1704294434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51161-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,3]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["51161"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-51161-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.11.11.22282219","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,3]]},"assertion":[{"value":"17 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"464"}}